|
Bridgetech Asia Limited
("BT Asia")
is a leader in the
transfer of US FDA approved, CE Mark and/or late-stage Western medical
technology to Greater China with an initial focus on oncology. With operations both in
Greater China and the U.S., BT Asia is providing the most current medical
technology, including drugs, devices, and diagnostics for distribution
throughout Greater China.
BT Asia is supporting Greater China's increasing need for Western
healthcare products and services. China's middle class is estimated to
grow from 250 million people in 2003 to over 600 million people by 2020. As the
middle class increases, the demand grows for more sophisticated and readily
available healthcare products. The other regions of Greater China; Taiwan and
Hong Kong have a combined affluent population of 30 million.
BT Asia’s mission is to contribute to the well being of Greater
China's people through success in the marketplace. BT Asia has developed the
strategy, leadership and clinical infrastructure to evaluate and analyze the
best oncology products for Greater China’s healthcare market. BT Asia has
longstanding relationships with leading healthcare organizations both in the
U.S. and Greater China and close ties to government, regulatory and medical
communities in these regions. Through these relationships, market demand and
most importantly existing local sales and distribution infrastructure, BT Asia
is able to meet Greater China's growing healthcare needs.
Return to Top > |
